Gabapentin - Viatris
Alternative Names: CI 945; GABAPEN; GOE 3450; NeurontinLatest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Developer Pfizer; Viatris Inc
- Class Amines; Aminobutyric acids; Analgesics; Antiepileptic drugs; Antimanics; Antiparkinsonians; Anxiolytics; Cyclohexanecarboxylic acids; Gabapentinoids; Small molecules
- Mechanism of Action CACNA2D1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Epilepsy; Neuralgia; Neuropathic pain; Postherpetic neuralgia
- Discontinued Amyotrophic lateral sclerosis; Anxiety disorders; Bipolar disorders; Migraine; Spinal muscular atrophy
Most Recent Events
- 09 Jun 2010 First generic equivalent approved in USA for Postherpetic neuralgia
- 26 Jul 2006 Registered for Epilepsy in Japan (PO)
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma